Flu Season Starts Early: Data Shows 21% Jump in Sales

The shelves are already bare on October 9, 2026. Walgreens data, which ABC News accessed first, points to a 21.7 percent jump in cold and flu medication purchases compared to the same week last year. This is not a blip or a marketing fluke. It is a hard, measurable spike that tells us the respiratory virus season has moved up by weeks.

Timing is the key issue. In the last two seasons, flu activity stayed low until early November. This year, the numbers jumped in mid September. For doctors and patients, this compressed timeline changes the math on prevention. The window for protection is open, but the clock is running much faster than usual.

The Data Behind the Early Onset

Epic Research, which handles most electronic health records in the U.S., confirmed the trend on Thursday. Flu rates, defined as a diagnosis or positive test, hit 140 per 100,000 patients in the week of September 13. That is a major benchmark. In the 2024 and 2025 seasons, that threshold was not crossed until seven weeks later.

This is the earliest start in five years. The last time we saw such high activity in mid September was 2020 or 2021, but those years were driven by a different pathogen. Now, the influenza virus is driving the surge on its own. The match between Walgreens sales and Epic clinical data suggests this is a broad, population level shift, not an isolated regional event.

The Vaccination Gap

The early start reveals a worrying pattern in vaccination timing. Walgreens data from last season shows a clear lag in action. In New York and Texas, vaccination rates jumped by 68 percent and 54 percent respectively, but only one week after those states hit high levels of flu activity.

This lag is dangerous. Immunity from the flu shot takes about two weeks to build. By the time people rushed to get vaccinated after the surge began, they had missed the window for optimal protection during the peak. With the surge starting in September this year, there is still time to act. But waiting for symptoms to appear in the community before getting vaccinated is a strategy that fails to protect the individual during the most critical period.

What the Vaccine Actually Does

The seasonal flu vaccine is not a one size fits all solution, but it is targeted. It protects against three specific viruses predicted to circulate this season: the Type A (H1N1) virus, the Type A (H3N2) virus, and the Type B/Victoria virus. Knowing which strains are included explains why the vaccine is updated annually and why timing matters so much.

For older adults over 65, there is an additional option. They may be eligible for a higher dose version of the vaccine, designed to trigger a stronger immune response. This group is often at higher risk for severe complications, making the choice of vaccine formulation and the timing of administration even more critical than for younger adults.

The Practical Implications

Health authorities have a clear, consistent recommendation. The flu shot is recommended for everyone over 6 months old. This includes children, adults, and seniors. The early 2026 data suggests that the standard advice to wait for the fall to get vaccinated may need adjusting. If the season starts in September, the vaccination campaign needs to be fully active now.

Pharmacies and clinics are seeing an uptick in demand for cough drops, up 16.6 percent, as well as the broader category of cold and flu medicines. This shows people are already managing symptoms. However, treating after infection is always less effective than preventing it. The data serves as a clear call to action for those who have not yet received their shot.

Looking Ahead

Walgreens history shows that flu activity typically starts increasing around the end of September and ramps up significantly in December. With the early start this year, the peak could arrive sooner than expected. This puts pressure on healthcare systems and individual immune systems alike.

The convergence of sales data and clinical records paints a clear picture. The season is here. The question is not whether flu activity will rise, but how high it will go and how many people will be protected in time. The data from the first three weeks suggests a robust, early start, and the next few weeks will determine the trajectory for the rest of the winter.